Cyclosporine Ophthalmic

Major

Cyclosporine Ophthalmic Nifedipine Adalat® Increased NIFEdipine exposure, increased cycloSPORINE exposure and an increased risk of gingival hyperplasia Details Cyclosporine Ophthalmic Niflumic Acid An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Nimesulide An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Nimesulide Beta Cyclodextrin An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Nirmatrelvir Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Nirogacestat Ogsiveo Increased nirogacestat/CYP3A substrate exposure and an increased risk of nirogacestat/CYP3A substrate-related adverse effects Details Cyclosporine Ophthalmic Nomegestrol Increased cycloSPORINE exposure and an increased risk of cycloSPORINE toxicity (renal dysfunction, cholestasis, paresthesias) Details Cyclosporine Ophthalmic Norethindrone Aygestin Increased cycloSPORINE exposure and an increased risk of cycloSPORINE toxicity (renal dysfunction, cholestasis, paresthesias) Details Cyclosporine Ophthalmic Norgestimate Increased cycloSPORINE exposure and an increased risk of cycloSPORINE toxicity (renal dysfunction, cholestasis, paresthesias) Details Cyclosporine Ophthalmic Norgestrel Increased cycloSPORINE exposure and an increased risk of cycloSPORINE toxicity (renal dysfunction, cholestasis, paresthesias) Details Cyclosporine Ophthalmic Obeticholic Acid Ocaliva Increased risk of liver dysfunction Details Cyclosporine Ophthalmic Octreotide Bynfezia Reduced cycloSPORINE exposure and reduced efficacy of cycloSPORINE Details Cyclosporine Ophthalmic Olaparib Lynparza Increased olaparib exposure Details Cyclosporine Ophthalmic Olmesartan Benicar An increased risk of hyperkalemia Details Cyclosporine Ophthalmic Ombitasvir Increased cycloSPORINE plasma concentrations; increased ombitasvir plasma concentrations Details Cyclosporine Ophthalmic Omeprazole Gastrobim Altered cycloSPORINE exposure and an increased omeprazole exposure Details Cyclosporine Ophthalmic Orlistat Alli Reduced cycloSPORINE exposure Details Cyclosporine Ophthalmic Osimertinib Tagrisso Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Oxaprozin Coxanto An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Oxcarbazepine Oxtellar Reduced cycloSPORINE exposure Details Cyclosporine Ophthalmic Oxycodone Oxaydo Increased oxyCODONE exposure Details Cyclosporine Ophthalmic Oxyphenbutazone An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Paclitaxel Abraxane Increased PACLitaxel exposure Details Cyclosporine Ophthalmic Paclitaxel Protein-Bound Increased PACLitaxel exposure Details Cyclosporine Ophthalmic Pacritinib Vonjo® Altered (reduced/increased) CYP3A4/P-gp substrate with NTI exposure, an increased risk of CYP3A4/P-gp substrate with NTI-related a... Details Cyclosporine Ophthalmic Palbociclib Ibrance Increased exposure to CYP3A substrates with a narrow therapeutic index Details Cyclosporine Ophthalmic Palovarotene Sohonos Increased palovarotene exposure and an increased risk of palovarotene-related adverse effects Details Cyclosporine Ophthalmic Paltusotine Palsonify Reduced cycloSPORINE exposure Details Cyclosporine Ophthalmic Parecoxib An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Paritaprevir Increased exposure of cycloSPORINE and paritaprevir Details Cyclosporine Ophthalmic Paroxetine Paxil Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Pazopanib Votrient Increased cycloSPORINE plasma concentrations and risk of cycloSPORINE toxicity Details Cyclosporine Ophthalmic Pemigatinib Pemazyre Increased pemigatinib exposure and increased risk and severity of adverse reactions Details Cyclosporine Ophthalmic Pentazocine Increased pentazocine plasma concentrations and increased risk of respiratory depression Details Cyclosporine Ophthalmic Perindopril Aceon Acute renal dysfunction and an increased risk of hyperkalemia Details Cyclosporine Ophthalmic Pexidartinib Turalio Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Phenobarbital Fidoquel Reduced cycloSPORINE exposure and reduced efficacy of cycloSPORINE Details Cyclosporine Ophthalmic Phenylbutazone Equi-Phar An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Phenytoin Dilantin Reduced cycloSPORINE exposure and potentially increased risk of organ rejection Details Cyclosporine Ophthalmic Pibrentasvir Increased pibrentasvir exposure and an increased cycloSPORINE exposure Details